Jefferies Group Reiterates “Hold” Rating for Catalent Inc (CTLT)
Catalent Inc (NASDAQ:CTLT)‘s stock had its “hold” rating reissued by analysts at Jefferies Group in a report issued on Thursday. They presently have a $28.00 target price on the stock, up from their prior target price of $25.00. Jefferies Group’s price target indicates a potential upside of 8.36% from the company’s previous close.
Several other analysts have also recently weighed in on the stock. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $30.00 price objective (down previously from $30.50) on shares of Catalent in a research note on Tuesday, August 30th. Morgan Stanley reissued a “hold” rating on shares of Catalent in a report on Tuesday, August 30th. TheStreet raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 17th. Zacks Investment Research lowered shares of Catalent from a “hold” rating to a “strong sell” rating in a report on Monday, August 15th. Finally, Wells Fargo & Co. raised shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $28.67.
Catalent (NASDAQ:CTLT) opened at 25.84 on Thursday. The firm has a market capitalization of $3.22 billion and a price-to-earnings ratio of 29.03. The company has a 50-day moving average of $25.22 and a 200 day moving average of $25.66. Catalent has a one year low of $18.92 and a one year high of $32.24.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, August 29th. The company reported $0.52 earnings per share for the quarter, missing the consensus estimate of $0.53 by $0.01. The business had revenue of $532.20 million for the quarter. During the same period in the previous year, the business posted $0.61 earnings per share. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, analysts anticipate that Catalent will post $1.40 EPS for the current year.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the firm’s stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $23.58, for a total value of $403,234,623.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Several large investors have recently made changes to their positions in CTLT. GW&K Investment Management LLC raised its stake in shares of Catalent by 2.7% in the second quarter. GW&K Investment Management LLC now owns 1,755,362 shares of the company’s stock valued at $40,356,000 after buying an additional 46,305 shares during the period. Eagle Asset Management Inc. raised its stake in shares of Catalent by 21.1% in the second quarter. Eagle Asset Management Inc. now owns 112,315 shares of the company’s stock valued at $2,582,000 after buying an additional 19,579 shares during the period. Acadian Asset Management LLC raised its stake in shares of Catalent by 46,852.1% in the second quarter. Acadian Asset Management LLC now owns 316,927 shares of the company’s stock valued at $7,285,000 after buying an additional 316,252 shares during the period. LS Investment Advisors LLC raised its stake in shares of Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock valued at $164,000 after buying an additional 3,280 shares during the period. Finally, Louisiana State Employees Retirement System raised its stake in shares of Catalent by 4.4% in the second quarter. Louisiana State Employees Retirement System now owns 28,500 shares of the company’s stock valued at $655,000 after buying an additional 1,200 shares during the period.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.